Journal article icon

Journal article

Non-fatal overdose risk during and after opioid agonist treatment: a primary care cohort study with linked hospitalisation and mortality records

Abstract:

Background: The initiation and cessation of opioid agonist treatment (OAT) have both been associated with elevated risk of fatal overdose. We examined risk of non-fatal overdose during OAT initiation and cessation and specifically between methadone versus buprenorphine recipients.

Methods: We utilised primary care electronic health records from the Clinical Practice Research Datalink to delineate a study cohort of adults aged 18-64 who were prescribed OAT between Jan 1, 1998 and Dec 31, 2017. These records were linked to hospitalisation, mortality records and patient neighbourhood and practice-level Index of Multiple Deprivation quintiles. With inverse probability treatment weights applied and negative binomial regression models we estimated incidence rate ratios for hospital admissions among patients who experienced multiple overdoses.

Findings: A total of 20898 patients were prescribed methadone or buprenorphine over 83856 person-years of follow-up. Compared with periods in treatment, patients not in treatment were 51% more likely to experience a non-fatal overdose that required hospitalisation (weighted rate ratio, wRR 1·51; 95% CI 1·42, 1·60), especially during the four weeks of OAT initiation (5·59; 5·31, 5·89) and following cessation (13·39; 12·78, 14·03). The wRR of overdose during (0·37; 0·34, 0·39) and after treatment (0·36; 0·34, 0·38) favoured buprenorphine compared to methadone.

Interpretation: OAT is associated with decreased non-fatal overdose risk. Buprenorphine may act more protectively than methadone, especially during the first four weeks of treatment.

Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.lanepe.2022.100489

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0002-0096-1288
More by this author
Role:
Author
ORCID:
0000-0001-7336-1606
More by this author
Role:
Author
ORCID:
0000-0003-4630-2357
More by this author
Role:
Author
ORCID:
0000-0002-2958-915X


More from this funder
Funder identifier:
https://ror.org/0187kwz08
Grant:
NIHR-INF-0740


Publisher:
Elsevier
Journal:
Lancet Regional Health Europe More from this journal
Volume:
22
Article number:
100489
Publication date:
2022-08-11
Acceptance date:
2022-07-22
DOI:
EISSN:
2666-7762
Pmid:
36034051


Language:
English
Keywords:
Pubs id:
2041672
Local pid:
pubs:2041672
Deposit date:
2024-11-10

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP